Deval L Patrick is of Cerevel Therapeutics Holdings, Inc.. Currently has a direct ownership of 0 shares of CERE, which is worth approximately $0. The most recent transaction as insider was on Aug 01, 2024, when has been sold 13,743 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
100.0% 12M change
Total Value Held $0

DEVAL L PATRICK Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 01 2024
SELL
Sale (or disposition) back to the issuer
-
13,743 Reduced 100.0%
0 Common Stock
Jun 05 2024
BUY
Grant, award, or other acquisition
-
10,461 Added 43.22%
13,743 Common Stock
Nov 01 2023
SELL
Open market or private sale
$753,250 $25.0 p/Share
30,130 Reduced 90.18%
3,282 Common Stock
Nov 01 2023
BUY
Exercise of conversion of derivative security
$380,240 $12.62 p/Share
30,130 Added 47.42%
33,412 Common Stock
Jun 07 2023
BUY
Grant, award, or other acquisition
-
3,282 Added 50.0%
3,282 Common Stock
Sep 12 2022
SELL
Open market or private sale
$1,468,360 $30.78 p/Share
47,705 Reduced 100.0%
0 Common Stock
Sep 12 2022
BUY
Exercise of conversion of derivative security
$602,037 $12.62 p/Share
47,705 Added 50.0%
47,705 Common Stock

Also insider at

TWLO
TWILIO INC Communication Services
TOST
Toast, Inc. Technology
GBT
Global Blood Therapeutics, Inc. Healthcare
AMWL
American Well Corp Healthcare
GRNA
GreenLight Biosciences Holdings, PBC Healthcare
DLP

Deval L Patrick

Cambridge, MA

Track Institutional and Insider Activities on CERE

Follow Cerevel Therapeutics Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CERE shares.

Notify only if

Insider Trading

Get notified when an Cerevel Therapeutics Holdings, Inc. insider buys or sells CERE shares.

Notify only if

News

Receive news related to Cerevel Therapeutics Holdings, Inc.

Track Activities on CERE